slide1.jpg

NEWS!

We have developed
blood cells, 
cMylc, 
for
research of COVID-19!

We have developed a human white blood cells, cMylc, based on Mylc cell optimized for the evaluation of the efficacy and safety of vaccines and drugs for COVID-19, which is shaking the world!
High precision and uniform blood cells produced using regenerative medicine technologies drastically accelerate the evaluation of the efficacy of drugs for COVID-19.
(Please contact us for details.)

We are providing high precision immature blood cells developed for various types of evaluation of drugs and
functional materials for cosmetics and foods,
and offer a contract evaluation service using the blood cells.

© 2019 MiCAN Technologies Inc.

615-8245  京都市西京区御陵大原1-36 京大桂ベンチャープラザ

KKVP, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan